NCT06863805 Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
| NCT ID | NCT06863805 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Thyroid Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2022-12-15 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2022-12-15 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices
Eligibility Criteria
Inclusion Criteria: * Signed written informed consent, * Adult (≥18 years) male or female patients * Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review, * well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy, * Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue, * Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA). Exclusion Criteria: * Patients already receiving previous lines of systemic therapy, * Patients not eligible for systemic therapy.
Contact & Investigator
Manuela Ianni
STUDY CHAIR
Ospedale S. Orsola-Malpighi
Frequently Asked Questions
Who can join the NCT06863805 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06863805 currently recruiting?
Yes, NCT06863805 is actively recruiting participants. Contact the research team at margherita.nannini@unibo.it for enrollment information.
Where is the NCT06863805 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06863805 clinical trial?
NCT06863805 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Manuela Ianni at Ospedale S. Orsola-Malpighi. The trial plans to enroll 10 participants.